William Aliski - 10 Jun 2024 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Director
Issuer ticker: XFOR
Reported as of: 10 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2024, 16:13:25 UTC
Prior SEC filing: 14 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Adam S. Mostafa, attorney-in-fact

Key filing fact

William Aliski filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 11 Jun 2024.

Key facts

This page summarizes William Aliski's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Jun 2024, 16:13.

Change

Previous filing in this sequence was filed on 14 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Award

Transaction value: $0
Shares: +45,000
Change %: +87%
Price: $0.000000
Shares after: 96,667
Date: 10 Jun 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.